Table 3.
Echocardiography, cardiac magnetic resonance imaging and laboratory findings at 6-month follow-up.
| Measurements | Overall | Patients with cardiac injury | Patients without cardiac injury | p |
|---|---|---|---|---|
| (n = 27) | (n = 13) | (n = 14) | ||
| ECHO parameters | ||||
| LA (mm) | 34 [30, 38] | 31 [30, 34] | 35 [34, 38] | 0.094 |
| LV (mm) | 45 [43, 47] | 44 [42, 47] | 46 [44, 48] | 0.135 |
| RA (mm) | 38 [35, 41] | 38 [35, 41] | 38 [36, 40] | 0.897 |
| RV (mm) | 25 [21, 29] | 23 [20, 29] | 26 [22, 29] | 0.340 |
| IVS (mm) | 10 [9, 11] | 10 [9, 10] | 11 [9, 11] | 0.155 |
| LVPW (mm) | 10 [9, 11] | 10 [9, 10] | 11 [9, 11] | 0.134 |
| LVEF (%) | 60 [56, 66] | 61 [53, 66] | 60 [57, 66] | 0.700 |
| TAPSE | 27 [26, 30] | 26 [22, 29] | 27 [26, 30] | 0.187 |
| CMR parameters | ||||
| LGE n (%) | 8 (29.6) | 7 (53.8) | 1 (7.1) | 0.013 |
| LVEF (%) | 56 [54, 59] | 55 [53, 58] | 57 [54, 59] | 0.537 |
| EDV (mL) | 94 [89, 106] | 93 [88, 100] | 95 [90, 109] | 0.498 |
| ESV (mL) | 43 [37, 49] | 42 [34, 46] | 43 [39, 50] | 0.878 |
| Myo mass (g) | 65 [57, 73] | 63 [51, 70] | 68 [60, 75] | 0.230 |
| CO (L/min) | 3.5 [3.1, 3.9] | 3.2 [2.7, 3.6] | 3.8 [3.3, 3.9] | 0.196 |
| Cl (L/min/m2) | 2.1 [1.8, 2.3] | 2.1 [1.8, 2.3] | 2.0 [1.8, 2.3] | 0.805 |
| EDVI (mL/m2) | 57 [52, 63] | 60 [54, 66] | 54 [50, 61] | 0.206 |
| ESVI (mL/m2) | 25 [22, 31] | 26 [23, 31] | 24 [22, 29] | 0.422 |
| SVI (mL/m2) | 33 [29, 37] | 33 [29, 38] | 32 [28, 34] | 0.371 |
| Myo mass index (g/m2) | 38 [35, 43] | 40 [33, 43] | 38 [35, 42] | 0.975 |
| T1 mapping | 1211.7 [1185.2, 1247.1] | 1242.6 [1202.6, 1265.3] | 1205.1 [1179.0, 1236.5] | 0.196 |
| ECV | 0.28 [0.26, 0.31] | 0.28 [0.25, 0.30] | 0.29 [0.27, 0.31] | 0.618 |
| Laboratory findings | ||||
| ALT (U/L) | 20 [13, 29] | 23 [16, 36] | 16 [12, 28] | 0.152 |
| AST (U/L) | 22 [16, 29] | 29 [19, 30] | 17 [14, 24] | 0.004 |
| LDH (U/L) | 198 [164, 218] | 217 [212, 224] | 168 [151, 187] | 0.001 |
| Creatinine (umol/L) | 58 [50, 68] | 65 [57, 78] | 52 [47, 60] | 0.016 |
| hs-cTnI (pg/mL) | 2.9 [2.0, 4.4] | 4.3 [2.0, 6.7] | 2.5 [1.8, 2.9] | 0.041 |
| NT-proBNP (pg/mL) | 73 [49, 100] | 99 [78, 138] | 47 [36, 61] | 0.004 |
| hs-CRP (mg/L) | 0.9 [0.6, 2.1] | 0.8 [0.5, 2.0] | 1.5 [0.8, 2.2] | 0.356 |
| IL-6 (pg/mL) | 1.5 [1.5, 1.9] | 1.5 [1.5, 1.5] | 1.7 [1.5, 3.0] | 0.117 |
| D-dimer (ng/mL) | 146 [103, 230] | 152 [138, 213] | 120 [90, 230] | 0.227 |
| ST2 (ng/mL) | 14.1 [9.8, 17.9] | 16.6 [12.1, 22.5] | 12.5 [9.5, 16.7] | 0.044 |
ECHO, echocardiography; CMR, Cardiac Magnetic Resonance; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; IVS, interventricular septum; LVPW, left ventricular posterior wall; SV, stroke volume; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion; EDV, end-diastolic volume; ESV, end-systolic volume; CO, cardiac output; CI, cardiac index; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; SVI, stroke volume index; ECV, extracellular volume; ALT, glutamic-pyruvic transaminase; AST, glutamic-oxalacetic transaminease; LDH, lactate dehydrogenase; hs-cTnI, high-sensitivity cardiac troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6.